secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ambrx Biopharma, Inc. (—)
CIK:        0001990550
Form:       8-K
Filed at:   2024-03-07T23:59:59+00:00
Accession:  0001193125-24-061543
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Johnson & Johnson completes acquisition of Ambrx Biopharma for $2.0B; shareholders receive $28.00/share
--------------------------------------------------------------------------------

- Merger completed on March 7, 2024; each Ambrx share converted into $28.00 cash, no interest.
- Johnson & Johnson paid ~$2.0B equity value ($1.9B net of cash acquired) from cash on hand.
- Nasdaq trading halted March 7; shares to be delisted and deregistered under Exchange Act.
- CEO Daniel O'Connor ceased employment post-merger; entitled to severance and accelerated $10.5M restricted cash award.
- All six directors resigned; Johan Verbeeck and Allen Y. Kim became directors of surviving entity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1990550/000119312524061543/0001193125-24-061543-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1990550/000119312524061543/d750145d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-061543

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer